Navigation Links
Pfizer to Present More Than 40 Abstracts on Pre-Clinical, Clinical and Outcomes Research at Alzheimer's Association International Conference on Alzheimer's Disease
Date:7/8/2010

2010 highlights Pfizer's strategic approach to the discovery and development of potential new medicines as it underscores our effort to focus on a range of promising pathological targets.  We are committed to advancing the science of AD, with the ultimate goal of delivering innovative and meaningful new treatment options to patients."

The compounds in Pfizer's pipeline target many of the pathways thought to be implicated in Alzheimer's disease.  The data that will be presented at ICAD 2010 focus on several of these approaches, including:

Beta Amyloid Passive Immunotherapy: The most prominent theory currently is the beta amyloid hypothesis, which is based on evidence that the accumulation of beta amyloid, a toxic protein, is a defining characteristic of AD.  It is believed that reducing brain beta amyloid accumulation by inhibiting the production of beta amyloid and/or removing beta amyloid from the brain may slow the progression of the disease.  In passive immunotherapy, monoclonal antibodies are directed against beta amyloid facilitating removal of beta amyloid and thus reducing its accumulation in the brain.

Pfizer, together with Janssen Alzheimer Immunotherapy, its collaborator on the Alzheimer's Immunotherapy Program, is presenting a new exploratory analysis of pooled data from two Phase II studies on an investigational monoclonal antibody therapy.  Pfizer also is presenting several Phase I studies on another investigational monoclonal antibody therapy.

PDE Inhibition: The PDE enzyme family is thought to play a role in influencing synapse communication and stability, which is compromised in Alzheimer's disease.  Regulating the actions of these enzymes may potentially improve information processing, attention, memory and executive functioning.


'/>"/>
SOURCE Pfizer Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Wyeths Torisel and Roche/Genentechs Avastin Will Challenge Pfizers Sutent to Become the Clinical Gold Standard for Treatment of Metastatic Renal Cell Carcinoma
2. Kosans Motilin Receptor Agonist, Licensed to Pfizer, Enters Phase 1 Clinical Trial in Gastroesophageal Reflux Disease
3. Coley Pharmaceutical Group and Pfizer Nominate Additional Anti-Cancer Compound for Clinical Development
4. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
5. NicOx Announces Pfizer Initiates Phase 2 Clinical Development for PF-03187207 in Japan
6. Tacere Therapeutics Enters Collaboration and License Agreement With Pfizer To Develop and Commercialize RNAi Hepatitis C Drug
7. MannKind Addresses Pfizers Announcement Regarding Exubera
8. Quark Pharmaceuticals Announces First Patient Dosing by Pfizer in Phase II Trial of RNAi Therapy in Diabetic Macular Edema
9. Silence Therapeutics to Receive $1.9m Milestone Payment as Pfizer and Quark Commence Phase II Trial
10. Medarex Receives Milestone Payment from Pfizer for Investigational New Drug Application Filing
11. Pfizer Contributes Critical Data to URMC Drug Safety Initiative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... 27, 2015  Valeant Pharmaceuticals International, Inc. (NYSE: ... its previously announced registered offering of common shares in ... Pursuant to the Offering, the Company issued 7,286,432 common ... aggregate gross proceeds of approximately $1.45 billion. On March ... and Exchange Commission a final prospectus supplement to its ...
(Date:3/27/2015)...   Hospira, Inc. (NYSE: HSP ... world,s leading provider of injectable drugs and infusion ... of biosimilarity of its proposed biosimilar, Epoetin Hospira, ... conditionally approved name of RETACRIT™, compared to the ... data were presented at the National Kidney Foundation ...
(Date:3/27/2015)... March 27, 2015  Delcath Systems, Inc. (NASDAQ: ... device company focused on oncology with an emphasis ... cancers, announces the reporting of data from a ... for Injection with the Delcath Hepatic Delivery System ... at the Society of Surgical Oncology (SSO) Annual ...
Breaking Medicine Technology:Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 2Valeant Pharmaceuticals Closes Offering Of $1.45 Billion Of Common Shares 3Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 2Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 3Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 4Data Highlighting Delcath's Melphalan/HDS Presented At The Society Of Surgical Oncology Annual Meeting 5
... Jan. 28, 2011 Drug safety remains front and ... the agency strives to improve the public,s perception of ... improving its reputation among consumers and recognizes that its ... important role in that effort. One issue ...
... Burg Simpson Eldredge Hersh & Jardine, P.C., one of the ... that shareholder, Seth. A. Katz, has been appointed by the ... the Plaintiffs, Steering Committee in the multidistrict litigation against DePuy Orthopaedics, ... Hip System. In August 2010, DePuy Orthopaedics, Inc., ...
Cached Medicine Technology:Navigating the Gray Areas of Post-Marketing Surveillance 2Burg Simpson Leads National Litigation Against DePuy Orthopaedics, Inc. 2
(Date:3/28/2015)... AZ (PRWEB) March 28, 2015 Coffee could ... also help protect you from gum disease, researchers have found. ... against gum disease. , Coffee contains antioxidants. Antioxidants fight gum ... the question researchers at Boston Univ. Henry M. Goldman School ... in the August 2014 issue of the Journal of Periodontology. ...
(Date:3/28/2015)... 2015 With more than 4,500 ... of osteoporosis, osteoarthritis and musculoskeletal diseases gathered here ... be the first time in the 17-year history ... the hot-button topic is an emerging non-pharmaceutical protocol ... scientific principles of Wolff’s law, osteogenic loading at ...
(Date:3/28/2015)... March 28, 2015 India Network ... is made available to all visitors who purchase the ... All members are encouraged to purchase the insurance program ... lack of proper coverage for pre-existing medical conditions. Parents ... or two medical conditions with serious consequences to their ...
(Date:3/28/2015)... 2015 One in three young athletes ... presented today at the American Orthopaedic Society for Sports ... the long term success of surgery for patients aged ... data from 242 patients who underwent ACL reconstruction between ... MBBS, FRACS, from North Sydney Orthopaedic and Sports Medicine ...
(Date:3/28/2015)... Genomic medicine experts have sequenced the ... the first time, key information for understanding and treating ... newly posted story on the Surviving Mesothelioma website. ... Columbia, the British Columbia Cancer Agency, and PhenoPath lab ... molecular alterations and mutations that can lead to ...
Breaking Medicine News(10 mins):Health News:New Research Impliments Coffee May Help Fight Gum Disease and Increasing Benefits With Tylers Coffee 2Health News:Non-Drug Protocol for Building Bone Density Expected to Steal Spotlight at World Congress on Osteoporosis 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 2Health News:India Network Health Insurance Today Announces New Eligibility Criteria for Pre-existing Condition Health Insurance Coverage for Visitors to the United States 3Health News:Young Athletes at Greater Risk for Re-Injury after ACL Surgery 2Health News:New Genomics Research May Help Doctors Tailor Mesothelioma Treatment, According to Surviving Mesothelioma 2
... to use fertility treatment to create a "saviour sibling" for ... has issued a licence to a clinic allowing it to ... will be a donor for a very ill baby. ... called diamond blackfan anaemia and her only hope of survival ...
... Stephanie Mullen, a type 1 diabetic has been reported missing ... run out of medication// leaving her gravely ill, police have ... left her home in Uphall, at 2 pm on Monday. ... female friend in Livingston. She is white, 5 ft 2in, ...
... by the defence attorneys of the AIIMS hospital, has sought ... where a boy, suffering from cancer, got inflicted with AIDS ... ,The victim, who was nine years old at the ... for treatment of cancer, supposedly has contracted HIV due to ...
... analyze the risk attitudes and consequences of college drinking ... takers compared to women// who are inclined to use ... drinking in the company of friends, counting the number ... of money spent on drinking. ,Steve Benton, ...
... have tolled up 100,000 hours of time as they collaborated ... bird flu.// Researchers eleven UK universities and research labs have ... could be effective against the H5N1 virus. ,The ... help particle physicists examine the huge amounts of data from ...
... of the child is not being revealed in Grampian. NHS there ... time it took up.// Expectant mothers are not being told about ... not because we are getting it wrong but because of time ... get the sex right. When you aggregate that over a day ...
Cached Medicine News:Health News:A Boy Undergoing Treatment For Cancer Gets AIDS At AIIMS 2Health News:Risk Attitudes And Consequences Of College Drinking 2Health News:UK Computer Grid In Bird Flu Fight 2Health News:UK Computer Grid In Bird Flu Fight 3
... Roche Diagnostics Task Targeted Automation ... state-of-the-art automation of pre- and ... decapping, sorting / archiving of ... bar code labeled secondary tubes. ...
... The Roche Diagnostics Task ... a state-of-the-art automation of ... the laboratories: decapping, sorting / ... aliquoting into bar code labeled ...
... Save precious time and gain efficiency ... Lab Automation System (LAS), the high-throughput ... sample-processing capabilities. The Olympus OLA2500 LAS ... designed for medium- to high-volume laboratories. ...
The Freedom EVO series platform offers a choice of flexible, scalable solutions for current and future application needs....
Medicine Products: